Downregulation of c-FLIP, XIAP and Mcl-1 protein as well as depletion of reduced glutathione contribute to the apoptosis induction of glycyrrhetinic acid derivatives in leukemia cells.

Abstract:

:The antiproliferative effects and apoptosis inducing abilities of four 18beta-glycyrrhetinic acid (GA) derivatives, methyl 2-cyano-3,11-dioxooleana-1,12-dien-30-oate (CDODO-Me-11), methyl 2-cyano-3,12-dioxooleana-1,12-dien-30-oate (CDODO-Me-12) and their non-esters were investigated in human leukemia cells. Methyl esterification and switching a keto group from position C(11) to C(12) significantly increased the antiproliferative effects. CDODO-Me-11 and CDODO-Me-12 were 10-fold more potent than their non-esters, respectively. CDODO-Me-12 was 10-fold more effective than CDODO-Me-11 in inducing apoptosis which was correlated with the activation of caspase-8 and caspase-9. Western blot analyses revealed that CDODO-Me-12 and CDODO-Me-11 downregulated the levels of anti-apoptosis proteins, c-FLIP, XIAP and Mcl-1, without altering the protein levels of Bcl-2 and the death receptors DR4 and DR5. Both agents decreased the levels of the mitochondrial membrane potential without altering the intracellular H(2)O(2) levels. Jurkat cells without expression of caspase-8 were not sensitive to CDODO-Me-12, but were somewhat responsive to CDODO-Me-11. K562 cells with higher intracellular reduced glutathione (GSH ) levels were less responsive to CDODO-Me-12 apoptosis induction than U937 cells even though both cell lines were equally sensitive to CDODO-Me-11 apoptosis induction. Both agents depleted intracellular GSH levels and exogenous GSH reversed apoptosis induction by either agent in HL-60 cells. N-acetylcysteine (NAC) significantly attenuated apoptosis induction by CDODO-Me-12, but only weakly, that by CDODO-Me-11. UV spectrophotometric analysis revealed that both agents interacted with GSH while only CDODO-Me-12 had high reactivity with NAC. These data suggest that both agents induce apoptosis requiring to bind to functional proteins with thiol groups and that GSH may play a protective role by forming inactive adducts with them.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Song D,Gao Y,Wang R,Liu D,Zhao L,Jing Y

doi

10.4161/cbt.9.2.10287

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

96-108

issue

2

eissn

1538-4047

issn

1555-8576

pii

10287

journal_volume

9

pub_type

杂志文章
  • HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFβ activation.

    abstract::A right amount of oxygen and nutrients is essential for a tumor to develop. The role of oxygen dependent pathways and their regulators is therefore of utmost importance although little is known about the detailed impact they can have. Recently we have shown that inhibition of the oxygen sensor PHD2 in tumor cells bloc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.13.4.18830

    authors: Klotzsche-von Ameln A,Muschter A,Heimesaat MM,Breier G,Wielockx B

    更新日期:2012-02-15 00:00:00

  • Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells.

    abstract:BACKGROUND:Mutations that activate the PI3K/AKT/mTOR pathway are relatively common in urothelial (bladder) cancers, but how these pathway mutations affect AKT dependency is not known. We characterized the relationship between AKT pathway mutational status and sensitivity to the effects of the selective AKT kinase inhib...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.21793

    authors: Dickstein RJ,Nitti G,Dinney CP,Davies BR,Kamat AM,McConkey DJ

    更新日期:2012-11-01 00:00:00

  • Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer.

    abstract::Triple-negative breast cancer (TNBC) represents a collection of malignant breast tumors that are often aggressive and have an increased risk of metastasis and relapse. Long non-coding RNAs are generally defined as RNA transcripts measuring 200 nucleotides or longer that do not encode for any protein. During the past d...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1040957

    authors: Chen C,Li Z,Yang Y,Xiang T,Song W,Liu S

    更新日期:2015-01-01 00:00:00

  • Invasive stratified mucin-producing carcinoma: a clinicopathological analysis of three cases.

    abstract::Objective: To investigate the clinicopathologic features and immunophenotype of invasive-stratified mucin-producing carcinoma (ISMC). Methods: We retrospectively analyzed three patients who underwent surgery for pathologically confirmed ISMC from January 2017 to December 2017 in Anyang Tumor Hospital. The pathological...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1647054

    authors: Lei R

    更新日期:2019-01-01 00:00:00

  • Colorectal cancer: new advances in immunotherapy.

    abstract::Colorectal cancer remains the second leading cause of cancer-related mortality in the United States. Although surgical resection is still the primary treatment for colorectal cancer, in recent years, there has been a remarkable progress in the development of new therapies to treat colorectal cancer. Response rates hav...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.6.1.3672

    authors: Cubas R,Li M,Chen C,Yao Q

    更新日期:2007-01-01 00:00:00

  • Inactivation of miR-100 combined with arsenic treatment enhances the malignant transformation of BEAS-2B cells via stimulating epithelial -mesenchymal transition.

    abstract::Chronic arsenic treatment induces epithelial-mesenchymal transition (EMT) and promotes tumorigenicity, but the mechanism is unclear. MiR-100 has been shown to be involved in this biologic process. In this study, we hypothesize that inactivation of miR-100 combined with low concentration of arsenic exposure could promo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1345393

    authors: Yang J,Chen Z,Wang X,Xu M,Fang H,Li F,Liu Y,Jiang Y,Ding Y,Li J,Wang S

    更新日期:2017-12-02 00:00:00

  • Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2.

    abstract::5-fluorouracil (5-FU) is the major chemotherapeutic agent for treatment of colorectal carcinoma, but the molecular mechanisms of response and resistance are not understood completely. We therefore studied the 5-FU dose response and time course of gene expression transcriptome changes in colon carcinoma cell lines that...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.2.5.532

    authors: Zhang W,Ramdas L,Shen W,Song SW,Hu L,Hamilton SR

    更新日期:2003-09-01 00:00:00

  • Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.

    abstract::Polo-like kinase 1 (Plk1) is a key cell cycle regulator that is frequently overexpressed in human hepatocellular carcinomas. Blockade of the Plk1 pathway has been reported to be capable of inducing anti-tumor effect. Here, plasmids containing U6 promoter-driven shRNAs against human Plk1 were constructed and transfecte...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.4.14178

    authors: Deng H,Jiang Q,Yang Y,Zhang S,Ma Y,Xie G,Chen X,Qian Z,Wen Y,Li J,Yang J,Chen L,Zhao X,Wei Y

    更新日期:2011-02-15 00:00:00

  • Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.

    abstract::Celecoxib exhibits cancer preventive and therapeutic effects in animal models and clinical trials. It presumably acts through selective inhibition of cyclooxygenase-2 (COX-2) and subsequent reduction of prostaglandin (PG) synthesis. However, the concentrations of celecoxib required for growth inhibition and apoptosis ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.4.1618

    authors: Sun SY,Schroeder CP,Yue P,Lotan D,Hong WK,Lotan R

    更新日期:2005-04-01 00:00:00

  • The promising role of nivolumab in renal cell cancers.

    abstract::The therapeutic efficacy of checkpoint inhibitors across numerous tumor types has resulted in approval for neoplasms such as melanoma and lung cancer. Nivolumab is a fully humanized IgG4 antibody that inhibits immune checkpoint between programmed death 1 (PD-1) on T cells and PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2)...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1139269

    authors: Gupta K,Tiu DY,Tiu J,Aragon-Ching JB

    更新日期:2016-01-01 00:00:00

  • Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.

    abstract::Methylthioadenosine phosphorylase (MTAP), a key enzyme in the catabolism of 5'-deoxy-5'-methylthioadenosine (MTA), catalyzes the formation of adenine and 5-methylthioribose-1-phosphate. MTAP is expressed in all cells throughout the body, but a significant percentage of human tumors have lost MTAP expression, thereby m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.21115

    authors: Tang B,Testa JR,Kruger WD

    更新日期:2012-09-01 00:00:00

  • Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

    abstract::TRA-8, a monoclonal antibody targeting death receptor, has demonstrated high therapeutic effect for triple negative breast cancer (TNBC) in preclinical models. Tamoxifen, the standard of care for ERα-positive breast cancer, induces apoptosis via ERβ, which commonly presents in TNBC cells. The current study investigate...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29183

    authors: Kim H,Samuel SL,Zhai G,Rana S,Taylor M,Umphrey HR,Oelschlager DK,Buchsbaum DJ,Zinn KR

    更新日期:2014-08-01 00:00:00

  • 5-hydroxymethylcytosine: a new insight into epigenetics in cancer.

    abstract::DNA methylation at the 5 position of cytosine (5-mC) has emerged as a key epigenetic marker that plays essential roles in various biological and pathological processes. 5-mC can be converted to 5-hydroxymethylcytosine (5-hmC) by the ten-eleven translocation (TET) family proteins, which is now widely recognized as the ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.27144

    authors: Ye C,Li L

    更新日期:2014-01-01 00:00:00

  • Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells.

    abstract::Apoptosis induced by interferon-alpha (IFNalpha) is associated with induction of TRAIL in a number of different cell types. Here we examined whether or not TRAIL was required for apoptosis in a model human bladder cancer cell line (UM-UC-12) and defined the molecular mechanisms involved in IFNalpha-induced TRAIL expre...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.6.4088

    authors: Papageorgiou A,Dinney CP,McConkey DJ

    更新日期:2007-06-01 00:00:00

  • Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.

    abstract::The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objecti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1809913

    authors: Chau V,Madan RA,Figg WD

    更新日期:2020-10-02 00:00:00

  • Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

    abstract::Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 kinase (PI3K)/Akt/mam...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26725

    authors: Okabe S,Tauchi T,Tanaka Y,Kitahara T,Kimura S,Maekawa T,Ohyashiki K

    更新日期:2014-02-01 00:00:00

  • The role of apoptosis in cancer cell survival and therapeutic outcome.

    abstract::A number of discoveries have clarified the molecular mechanism of apoptosis, thus clarifying the link between apoptosis and therapeutic outcome. Even though apoptosis is thought to play a major role in anticancer therapy, the clinical relevance of induction of apoptosis remains uncertain, particularly in solid tumors....

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.5.11.3456

    authors: Kim R,Emi M,Tanabe K

    更新日期:2006-11-01 00:00:00

  • LINC00958 regulated miR-627-5p/YBX2 axis to facilitate cell proliferation and migration in oral squamous cell carcinoma.

    abstract::Oral squamous cell carcinoma (OSCC), the subtype of head and neck cancers, is notorious for its high incidence and death rate. The role of long non-coding RNAs (lncRNAs) is discovered to be significant for the canceration and cancer progression. Long intergenic non-protein coding RNA 958 (LINC00958) is discovered as a...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1617571

    authors: Chen F,Liu M,Yu Y,Sun Y,Li J,Hu W,Wang X,Tong D

    更新日期:2019-01-01 00:00:00

  • Randomized discontinuation trial of sorafenib (BAY 43-9006).

    abstract::With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/cbt.5.10.3290

    authors: Jain L,Venitz J,Figg WD

    更新日期:2006-10-01 00:00:00

  • The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.

    abstract::CP-31398, a styrylquinazoline, emerged from a screen for therapeutic agents that restore a wild-type DNA-binding conformation of mutant p53 to suppress tumors in-vivo (Science 286, 2507, 1999). We investigated the growth inhibitory mechanism of CP-31398 using nine human cancer cell lines containing wild-type, mutant o...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.1.1.41

    authors: Takimoto R,Wang W,Dicker DT,Rastinejad F,Lyssikatos J,el-Deiry WS

    更新日期:2002-01-01 00:00:00

  • Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy.

    abstract:BACKGROUND:Primary brain tumors have always been associated with high morbidity and mortality. Glioma is the most common type of malignant brain tumors,with a high probability of recurrence after surgical excision and with poor prognosis.The purpose of this study was to compare the therapeutic efficacy of computed tomo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.20834

    authors: Hu X,Qiu H,Zhang L,Zhang W,Ma Y,Qiao Z,Chen D,Han J,Duan G,Zhang F

    更新日期:2012-08-01 00:00:00

  • Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.

    abstract::Overall, NSCLC has a poor 5-year survival and new therapeutic approaches are urgently needed. ERBB-addicted NSCLC that have become resistant to ERBB inhibitors are often refractory to additional therapeutic interventions. The sphingosine-1-phosphate receptor modulator fingolimod (FTY720), approved for the treatment of...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1538616

    authors: Booth L,Roberts JL,Spiegel S,Poklepovic A,Dent P

    更新日期:2019-01-01 00:00:00

  • New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.

    abstract::Acute promyelocytic leukemia (APL) is one of the most fatal hematological malignancies. APL during pregnancy is a rare comorbidity and can lead to adverse outcomes, such as maternal and/or fetal death, without timely and appropriate management. Medical management for APL during pregnancy remains challenging. We report...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1529122

    authors: Li H,Han C,Li K,Li J,Wang Y,Xue F

    更新日期:2019-01-01 00:00:00

  • Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.

    abstract::The presence of tumor-infiltrating lymphocytes (TILs) in epithelial ovarian cancer indicates a host antitumor response and is associated with improved survival. We wished to determine the extent to which TIL density differs from site to site within a given patient. We initially studied multiple paired metastases from ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.4.16908

    authors: Hagemann AR,Hagemann IS,Cadungog M,Hwang WT,Patel P,Lal P,Hammond R,Gimotty PA,Chu CS,Rubin SC,Birrer MJ,Powell DJ Jr,Feldman MD,Coukos G

    更新日期:2011-08-15 00:00:00

  • Overexpression of Ecto-5'-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix.

    abstract::Ecto-5'-nucleotidase (CD73) was overexpressed in malignancies of epithelial origin and was involved in a variety of cellular processes such as cytoprotection and anti-inflammation. In the present study, human mammary T-47D cells were transfected with pcDNA-NT5E to establish a CD73 overexpressed cell model. Short small...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.3.3762

    authors: Zhou P,Zhi X,Zhou T,Chen S,Li X,Wang L,Yin L,Shao Z,Ou Z

    更新日期:2007-03-01 00:00:00

  • Renal angiomyolipoma (AML) harboring a missense mutation of TSC2 with copy-neutral loss of heterozygosity (CN-LOH).

    abstract::Angiomyolipoma (AML) is classified as a perivascular epithelioid cell neoplasm, mostly occurring in the kidney. Twenty percent of patients with renal AML have tuberous sclerosis complex (TSC) caused by germline variation in the TSC1 or TSC2 gene. In this paper, we report the first case of renal AML harboring somatic m...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2019.1702406

    authors: Idogawa M,Hida T,Tanaka T,Ohira N,Tange S,Sasaki Y,Uhara H,Masumori N,Tokino T,Natori H

    更新日期:2020-04-02 00:00:00

  • Absence of SV40 in Austrian tumors correlates with low incidence of mesotheliomas.

    abstract::Between 1955 and 1963 millions of people were worldwide vaccinated with polio-vaccines that were contaminated with the simian virus 40 (SV40). This tumor-inducing virus has subsequently been detected in several human tumors. In Austria, polio mass vaccination started in winter 1961/62 with a presumably SV40-free Briti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:

    authors: Leithner A,Weinhaeusel A,Windhager R,Schlegl R,Waldner P,Lang S,Dominkus M,Zoubek A,Popper HH,Haas OA

    更新日期:2002-07-01 00:00:00

  • A DNA repeat, NBL2, is hypermethylated in some cancers but hypomethylated in others.

    abstract::Hypermethylation at certain CpG-rich promoters and hypomethylation at repeated DNA sequences are very frequently found in cancers. We provide the first report that a DNA sequence (NBL2) can be either extensively hypermethylated or hypomethylated in cancer. Previously, it was shown that NBL2, a complex tandem DNA repea...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.4.1622

    authors: Nishiyama R,Qi L,Tsumagari K,Weissbecker K,Dubeau L,Champagne M,Sikka S,Nagai H,Ehrlich M

    更新日期:2005-04-01 00:00:00

  • Chetomin, a Hsp90/HIF1α pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells.

    abstract::Non-small cell lung cancer (NSCLC) remains recalcitrant to effective treatment due to tumor relapse and acquired resistance. Cancer stem cells (CSCs) are believed to be one mechanism for relapse and resistance and are consequently considered promising drug targets. We report that chetomin, an active component of Chaet...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1763147

    authors: Min S,Wang X,Du Q,Gong H,Yang Y,Wang T,Wu N,Liu X,Li W,Zhao C,Shen Y,Chen Y,Wang X

    更新日期:2020-08-02 00:00:00

  • Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.

    abstract::Although targeted therapy directed toward driver mutations has produced a significant efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not possess mutations associated with the approved targeted drugs. Angiogenic agents play an important role in the therapeutic strategy for advan...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2017.1414757

    authors: Wu F,Zhang S,Gao G,Zhao J,Ren S,Zhou C

    更新日期:2018-03-04 00:00:00